Jacobs Levy Equity Management, Inc Sage Therapeutics, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $23.9 Billion
- Q1 2025
A detailed history of Jacobs Levy Equity Management, Inc transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 706,390 shares of SAGE stock, worth $6.57 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
706,390
Previous 1,123,308
37.12%
Holding current value
$6.57 Million
Previous $6.1 Million
7.94%
% of portfolio
0.02%
Previous 0.02%
Shares
20 transactions
Others Institutions Holding SAGE
# of Institutions
218Shares Held
50MCall Options Held
220KPut Options Held
312K-
Black Rock Inc. New York, NY5.22MShares$48.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.08MShares$47.2 Million0.0% of portfolio
-
Madison Avenue Partners, LP New York, NY4.48MShares$41.6 Million4.6% of portfolio
-
Tig Advisors, LLC New York, NY2.73MShares$25.4 Million1.36% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.09MShares$19.4 Million0.02% of portfolio
About Sage Therapeutics, Inc.
- Ticker SAGE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,422,300
- Market Cap $553M
- Description
- Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...